Deuterated Reagents for Pharmaceuticals

Stable Isotope-Labeled Synthetic Intermediates

Deuterated Reagents for Pharmaceutical and Synthetic Applications

  • Deuterated Reagents for Pharmaceutical and Synthetic Applications


Stable Isotope-Labeled Synthetic Intermediates

In recent years, some pharmaceutical companies have begun to investigate deuteration of molecules that may provide advantages over their existing nondeuterated counterparts. In addition, increasing research into the potential medical advantages of new deuterated drugs is also occurring. 

The potential advantages of deuterated pharmaceuticals includes:

Improved metabolic profile. The improved metabolic profile may potentially reduce or eliminate unwanted side effects or undesirable drug interactions.

Improved oral bioavailability. Deuteration in some compounds has reduced the presystemic metabolism that occurs in the digestive track, allowing more of the unmetabolized drug to reach its target.

Increased half-life. Deuterated compounds can have a slower pharamacokinetic affect, extending the absorption and distribution in the body. This may decrease the number of doses a patient may require in certain time period compared to its nondeuterated counterpart.

Catalog No. Description
DLM-112  Acetaldehyde-d (D, 99%) 
DLM-12RG*  Acetic acid-d4 (D, 99%)
DLM-1556 Acetic acid-d (D, 98%)
DLM-1162 Acetic anhydride-d6 (D, 98%) 
DLM-9RG* Acetone-d6 (D, 99.5%) 
DLM-247 Acetyl chloride-d3 (D, 98%) 
DLM-855 Acrylic-2,3,3,-d3 acid (+ 0.1% 4-methoxyphenol) (D98%)  (<5% H2O)
Ammonium deuteroxide-d(D, 99%) (~25% Sol. In D2O)
DLM-862 Aniline-ring-d5, (D, 98%)
DLM-1RG*  Benzene-d6 (D, 99%)
DLM-494  Biphenyl- d10  (D, 98%) 
DLM-1315  Borane-d3, (D, 98%) (1 molar in THF) (+0.005M NaBD4) 
DLM-4747 Borane-d3 methylsulfide complex (D, 98%) (contains <10% additional dimethylsulfide)
DLM-398  Bromobenzene-d5, (D, 99%)
DLM-874 Bromoethane-d5, (D, 98%) 
DLM-181  1,4-Butanediol-2,2,3,3-d4 (D, 98%)
DLM-1664 tert-Butanol-d10, (D, 98%) 
DLM-1116  tert-Butyl chloride-d9 (D, 98%) 
DLM-263  Chlorobenzene-d5 (D, 99%) 
DLM-337 Chlorobenzene-d3 (D, 99%)
DLM-7RG Chloroform-d (D, 99.7%)
DLM-1560  Cyclohexanone-d10 (D, 98%)
DLM-2781 Cyclopentyl bromide-d9 (D, 98%)
DLM-1003DR Deuterium (D, 99.96) <400 ppm HD
DLM-408DR Deuterium (D, 99.8%) (D2, 99.6% + HD, 0.4%)
DLM-458DR Deuterium chloride (D, 99%)
DLM-3DR  Deuterium chloride (D, 99.5%) DCl 35% w/w solution in D2
DLM-2  Deuterium chloride (D, 99.5%) DCl 20% w/w solution in D2O
DLM-4DR Deuterium oxide (D, 99.9%)
DLM-4DR-99.8 Deuterium oxide (D, 99.8%)
DLM-195  1,2-Dibromoethane-d4 (D, 99%)
DLM-158 1,2-Dichlorobenzene-d4 (D, 99%)
Dimethyl-d6-amine:HCI (D,98%)
DLM-3903 Dimethyl carbonate-d6 (D, 99%)
DLM-196 Dimethyl sulfate-d6, (D, 98%) 
DLM-10RG* Dimethyl sulfoxide-d6 (D, 99.9%)
DLM-25 N,N-Dimethylformamide-d7 (D, 99.5%)
DLM-1670  N,N Dimethylformamide (formyl-D, 98-99%)
DLM-31 Ethanol-d6 (D, 99%) anhydrous
DLM-16 Ethanol-OD (D, 99%) <6% D2O
DLM-9660 N-Ethylaniline-d10 (D, 98%)
DLM-9626 N-Ethyl-d5-aniline (D, 98%)
DLM-347 Ethylene-d4 (D, 98%)
DLM-805 Formaldehyde-d2 (D, 98%) (~20% w/w in D2O)
DLM-286 Formic acid-d2 (D, 98%) (<5% D2O)
DLM-743 Formic acid (formyl-D, 98%) (<5% H2O)
DLM-423 n-Heptane-d16 (D, 98%)
DLM-1023 Iodoethane-1,1-d2 (D, 98%) + copper wire
DLM-1024 Iodoethane-2,2,2-d3 (D, 98%) + copper wire
DLM-272 Iodoethane-d5 (D, 99%) + copper wire
DLM-44 Isopropanol-d8 (D, 99%)
DLM-6201 a-Ketoglutaric acid-3,3,4,4-d (D, 98%) CP 90
DLM-1945  bis(2-Chloroethoxy)-d8-methane (D, 98%) 
DLM-1981 Methanesulfonic acid-d4 (D, 97-98%)
DLM-24RG* Methanol-d4 (D, 99.5%)
DLM-15 Methanol-OD (D, 99%)
DLM-651 Methyl formate (formyl-D, 99%)
DLM-362 Methyl iodide-d3 (D, 99.5%) + copper wire 
DLM-9707 Methyl-d3 methanesulfonate (D, 98%)
DLM-1500DR Methyl-d3-amine (D, 98%)
DLM-289 Methyl-d3-amine·HCl (D, 98%)
DLM-23RG Methylene chloride-d2 (D,99.8%)
DLM-3484  Morpholine-2,2,3,3,5,5,6,6-D8  (D, 98%)
DLM-295 2-Nitrophenol-ring-d4 (D, 98%)
DLM-296 4-Nitrophenol-ring-d4  (D,98%)
DLM-619 Octanoic acid-d15 (D, 98%)
DLM-300 Paraformaldehyde-d2 (D, 99%)
DLM-370 Phenol-d6 (D, 98%)
DLM-788 Phthalic anhydride-d4 (D, 98%)
DLM-9813 Pivalic acid-trimethyl-d9, (D, 98%)
DLM-9662 Pyrrolidine-2,2,3,3,4,4,5,5-d8 (D, 98%)
DLM-3078DR N-Propanol-d7 (D, 98%)
DLM-226 Sodium borodeuteride-d4 (D, 99%) CP 90-95%
DLM-45DR Sodium deuteroxide (D, 99.5%) 40% in D2O
DLM-1361 Sodium formate (D, 98%)
DLM-8206 Sodium 2,2-dimethyl-2silapentane-5-sulfonate-d6 (DSS) (D, 98%)
DLM-33DR Sulfuric acid-d2 (D, 99%) 96-98% in D2O
DLM-36 Tetrahydrofuran-d8 (D, 99.5%)
DLM-2729 Tetramethylsilane-d12 (D, 98%)
DLM-5RG* Toluene-d8,(D, 99.5%)
Trifluoroacetic acid-d (D. 98%)

*Reagent grade
CP = chemical purity

Frequently Asked Questions 

Do you have a D2O Recovery Program?

Yes, we do have a D2O Recovery Program. If you have D2O (deuterium oxide) currently that you would like to return for a potential credit, please visit our website and complete the necessary form or contact your customer service at 1-800-322-1174 (North America) or 1-978-749-8000 (International).

What do I do if I need multiple vials or carboys when returning D2O for the D2O Recovery Program?

If you have more than ~16 L you may require multiple carboys, please just ask. 

When returning D2O for the D2O Recovery Program should I fill the carboy to the top?

No! Fill the bulk carboy container ~80% full. Most are shipped by FedEx Air, and if full, the carboy is likely to expand and possibly rupture the container.



Faleb, E.; Ulanenko, K.; et. al 2017. A Highly Efficient Suzuki-Miyaura Methylation of Pyridines Leading to the Drug Pirfenidone and to its CD3 Version (SD-560), Green Chemistry Read article

Hamilton, P. 2017. Deuterated drugs are new chemical entities. JDSUPRA®  Read article

Mullard, A, 2016 Deuterated drugs draw heavier backing. Nature Reviews Drug Discovery, Published online 1 Apr 2016 PMID: 27032821

2015. Drugs that live long will prosper. The EconomistScience & Technology, Sept. 5 edition.  Read article


Tasha Agreste

Tasha Agreste

Deuterated Reagents & Intermediates Product Manager, China Sales - Research Products

Tasha is currently holds the position as the Deuterated Reagents and Intermediates Product Manager, where she focuses her time working with companies on their stable isotope-labeled product needs for synthetic applications, including the manufacturing of APIs.

"CIL would like to congratulate TEVA for their continuous groundbreaking work in the development of deuterated pharmaceuticals.
In April 2017, Teva received approval by the U.S. Food and Drug Administration (FDA) for the first deuterated drug product, deutetrabenazine tablets. 
We are extremely proud to be working with TEVA and their partners in this novel area providing high quality deuterated reagents and intermediates from research and development through commercialization."
CIL's Deuterated Reagents Team